Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Posts Q2 Revenue Rise, Widened Loss

SAN FRANCISCO, Aug. 5 - Ciphergen Biosystems today reported an increase in second-quarter revenue and a widened net loss.


For the three months ended June 30, Ciphergen reported total revenues of $8.7 million compared with $3.7 million for the same period one year ago. The company said the increase was due to inclusion of revenue from its BioSepra Process division, acquired in July 2001, and increased sales of its ProteinChip systems and arrays.


Net loss for the quarter increased to $7.3 million, or $.27 per share, compared to $5.8 million, or $.22 per share, for the year-ago period.


R&D spending rose to approximately $4.7 million compared to $3 million for the second quarter in 2001.


The company said it had roughly $63.7 million in cash, cash equivalents, and investments in securities as of June 30.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.